195 related articles for article (PubMed ID: 18227973)
1. Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Invest New Drugs; 2008 Oct; 26(5):407-15. PubMed ID: 18227973
[TBL] [Abstract][Full Text] [Related]
2. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
4. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.
Van Laar ES; Roth S; Weitman S; MacDonald JR; Waters SJ
Anticancer Res; 2004; 24(1):59-65. PubMed ID: 15015576
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Alexandre J; Kahatt C; Bertheault-Cvitkovic F; Faivre S; Shibata S; Hilgers W; Goldwasser F; Lokiec F; Raymond E; Weems G; Shah A; MacDonald JR; Cvitkovic E
Invest New Drugs; 2007 Oct; 25(5):453-62. PubMed ID: 17628744
[TBL] [Abstract][Full Text] [Related]
9. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
Hammond LA; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
Eur J Cancer; 2000 Dec; 36(18):2430-6. PubMed ID: 11094320
[TBL] [Abstract][Full Text] [Related]
12. [Antitumor activity of combination treatment combining gemcitabine with topotecin against human lung cancer xenografted in nude mice].
Fujita F; Koike M; Fujita M
Gan To Kagaku Ryoho; 2002 Apr; 29(4):577-84. PubMed ID: 11977542
[TBL] [Abstract][Full Text] [Related]
13. [Preclinical studies of oxaliplatin in combination chemotherapy].
Raymond E; Faivre S; Coudray AM; Louvet C; Gespach C
Bull Cancer; 2001 Aug; 88 Spec No():S26-34. PubMed ID: 11567911
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor activity of irofulven in combination with antimitotic agents.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Velasco TR; Estes LA; Suthipinijtham P
Invest New Drugs; 2002 Aug; 20(3):271-9. PubMed ID: 12201490
[TBL] [Abstract][Full Text] [Related]
15. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities.
Hou JM; Liu JY; Yang L; Zhao X; Tian L; Ding ZY; Wen YJ; Niu T; Xiao F; Lou YY; Tan GH; Deng HX; Li J; Yang JL; Mao YQ; Kan B; Wu Y; Li Q; Wei YQ
Oncology; 2005; 69(1):81-7. PubMed ID: 16088235
[TBL] [Abstract][Full Text] [Related]
16. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
[TBL] [Abstract][Full Text] [Related]
18. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.
Dings RP; Van Laar ES; Webber J; Zhang Y; Griffin RJ; Waters SJ; MacDonald JR; Mayo KH
Cancer Lett; 2008 Jul; 265(2):270-80. PubMed ID: 18378392
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
[TBL] [Abstract][Full Text] [Related]
20. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
Terranova N; Germani M; Del Bene F; Magni P
Cancer Chemother Pharmacol; 2013 Aug; 72(2):471-82. PubMed ID: 23812004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]